Cluster: Archive

More

Lonza CEO steps down over poor 2003 figures

This content was published on Jan 20, 2004 The results were particularly affected by restructuring costs stemming from poor sales to the company’s pharmaceutical customers. Lonza said its profit of SFr91 million ($71.73 million) had been adversely affected by a one-off charge of SFr100 million related to the closure of some of its fine chemicals facilities. Gemünd, who only took on the role…